What does this research mean for the field?

Influenza vaccination reduces cardiovascular mortality by 55% in patients with coronary artery disease, supporting its use in secondary prevention, although evidence for primary prevention remains not robust. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

July 27, 2015Open Access

Analysis of the Cochrane Review: Influenza Vaccines for Preventing Cardiovascular Disease. Cochrane Database Syst Rev. 2015;5:CD005050.

DCDaniel CaldeiraUniversity of Lisbon JCJoão CostaSan Antonio College ACAntónio Vaz CarneiroHospital Israelita Albert Einstein

Key Points

Key points are not available for this paper at this time.

Abstract

Influenza infections are associated to increased risk of cardiovascular events. The systematic review of Cochrane Collaboration evaluated the role of influenza vaccination on primary or secondary prevention of cardiovascular events. The meta-analysis of four randomized controlled trials with moderate quality, including 1 682 patients with coronary artery disease, showed a 55% risk reduction on cardiovascular mortality. Data evaluating the role of vaccination in primary cardiovascular prevention were not robust. Portuguese and international recommendations for influenza vaccination in patients with coronary artery disease are then supported by this systematic review.

Perguntar à IA

Bookmark

View Full Paper